Founded in 2002, ACEA Biosciences, Inc. is a privately owned biotechnology company that is pioneering the development and commercialization of high performance, cutting edge cell analysis instruments for life science research and clinical diagnostics. Employing noninvasive impedance microelectrodes in automated high-throughput plate formats, our xCELLigence® Real-Time Cell Analysis (RTCA) instruments maximize the physiological relevance of data extracted from in vitro cellular assays. These instruments enable label-free, real-time monitoring of cell proliferation, cell size/morphology, cell-substrate attachment quality, and cell invasion/migration. By eliminating the time- and labor-intensive steps of traditional methods, RTCA vastly improves efficiency and overall productivity. Moreover, the flexibility, sensitivity, and reproducibility of RTCA make it a standout amongst cell-based assay platforms. ACEA is also helping to revolutionize the field of flow cytometry by designing and producing high performance, customizable benchtop cytometers at accessible price points. By including features such as 13 fluorescence detection channels with 3 lasers, direct volumetric based cell counting, and a versatile high throughput walkaway autosampler, ACEA’s line of NovoCyte™ flow cytometers is raising the bar for what is expected of benchtop machines. xCELLigence® and NovoCyte™ instruments are currently being used worldwide in academic, industrial, and hospital labs for preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, clinical diagnostics, and basic research.